Clinical Trial: Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07667517) titled 'Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease' on June 14.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in adults with type 2 diabetes mellitus and chronic kidney disease (eGFR >= 30 mL/min/1.73 m^2 and UACR 30-2000 mg/g) who are already receiving a maximum tolerated dose of an ACE inhibitor or ARB. A total of 148 participants are randomized 1:1, stratified by baseline UACR (=300 mg/g), to oral fin...